Author: Benzinga Newsdesk | August 05, 2025 03:33pm
Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 12.46 percent. This is a 16.13 percent increase over losses of $(0.31) per share from the same period last year.